Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma
3 hours ago
- #Urothelial Carcinoma
- #First-line Treatment
- #Adjusted Comparison
- Adjusted comparison of first-line enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy ± avelumab maintenance for locally advanced/metastatic urothelial carcinoma (la/mUC).
- Modeling study using EV-302 patient-level data and JAVELIN-Bladder 100 study-level data to compare progression-free survival and overall survival.
- EV+P showed improved progression-free survival (HR 0.51, 95% CI 0.44-0.59) and overall survival (HR 0.64, 95% CI 0.49-0.86) versus PBC ± avelumab.
- Results consistent across sensitivity analyses, reinforcing EV+P as first-line standard of care in la/mUC, despite limitations like assuming all patients received avelumab.